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Spontaneous splenic rupture in lymphoproliferative disease is very rare. Herein, we report a case involving a
50-year-old man diagnosed with mantle cell lymphoma-blastoid variant who experienced spontaneous splenic rup-
ture. The patient underwent splenectomy and recovered without incident. At first histological examination of the
spleen suspected chronic lymphocytic leukemia. About one month after splenectomy multiple lymphadenopathy
developed. A lymph node biopsy resulted mantle cell lymphoma-blastoid variant. He received R-CHOP (rituxi-
mab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) , hyper-CVAD/MA chemotherapy (hyper-
fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with methotrexate and
cytarabine), and ICE therapy (ifosfamide, carboplatin, and etoposide). However despite intensive chemotherapies,
the disease became refractory, and the patient died 5 months after initiating chemotherapy. We discuss a case of
high-grade lymphoproliferative disease with spontaneous splenic rupture treated with splenectomy and chemo-
therapy.













：浅野千尋 〒276―8524 千葉県八千代市大和田新田 477―96 東京女子医科大学八千代医療センター血液内科
E-mail: asano.chihiro@twmu.ac.jp
doi: 10.24488/jtwmu.87.6_170




東女医大誌 第 87 巻 第 6号






Fig.　1　Computed tomography scan showing splenic rupture and intraperitoneal bleeding
Fig.　2　Histological findings of the lymph node
Large abnormal lymphocytes spread in diffuse (Hematoxylin and eosin stain (A) ) and were 















clin D1陽性でマントル細胞リンパ腫 blastoid vari-






表在リンパ節では顎下 φ1.5 cm，2個，左腋窩 φ4 cm，
左鼠径 3×8 cmを触知した． 眼球結膜に黄染なく，
眼瞼結膜に貧血なし．胸腹部に異常所見はなかった．
入院時検査所見：白血球 7,890/μl，Hb 10.8 g/dl，
血小板 25.2万/μlと軽度貧血を認め，LDH 251 U/l，
sIL-2R 5,350 U/lと上昇していた．





Fig.　3　Clinical course and treatment
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; Hyper-CVAD/MA, 
hyper-fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternat-














Table　1　Laboratory findings at the time of diagnosis
＜CBC＞ ＜Chemistry＞ ＜Bone marrow＞
RBC 386×104 /μl T-P 6.4 g/dl NCC 3.7×104 /μl
Hb 11.6 g/dl Alb 3.5 g/dl MgK 15.6 /μl
Ht 36.1 % AST 30 U/L G/E 4.71
WBC 4,920 /μl ALT 24 U/L Atypical lymphocytes 41.5 %
Neu 90.7 % LDH 257 U/L CD5＋ , CD19＋ , CD20＋
Eo 2.8 % G-GTP 14 U/L 46,XY [20]
Bas 0 % T-Bil 1.3 mg/dl
Lym 4.3 % BUN 15.4 mg/dl
Mom 2.2 % Cre 0.80 mg/dl
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